First Affiliated Hospital of Zhejiang University: Leukemia trials

The registry lists 11 Leukemia studies with First Affiliated Hospital of Zhejiang University as lead sponsor. 10 are open to participants now and 0 have results posted.

Early Phase 1 1Phase 2 9Phase 3 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Effectiveness and Safety of Blinatumomab and Donor Lymphocyte Infusion in Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Ph Negative B Cell Acute Lymphoblastic LeukemiaRecruitingNCT07105579Phase 2
• Effectiveness and Safety of InO±DLI for Relapsed B-ALL/LBL After Allo-HSCTNot yet recruitingNCT06861348Phase 2
• Clinical Study on the Safety and Efficacy of Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy for Adult Relapsed/Refractory Acute Myeloid Leukemia.Not yet recruitingNCT06786299Early Phase 1
• Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for Newly Diagnosed B-cell ALL Patients in CR1Not yet recruitingNCT06777264Phase 2
• Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALLRecruitingNCT06754267Phase 2
• VHAG in Treating R/R T-ALL/LBLRecruitingNCT06742463Phase 2
• Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALLRecruitingNCT06554626Phase 2
• Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDSNot yet recruitingNCT06050941Phase 2
• Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDSRecruitingNCT06046313Phase 2
• Modified TBF Regimen as Conditioning Regimen Prior to Allo-HSCT for T-ALL/LBLRecruitingNCT05598593Phase 2
• A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological MalignanciesActive, not recruitingNCT04547049Phase 3